While the 21st Century Cures Act that was recently approved is full of promise for healthcare innovation, experts warn against some of the Act's provisions.
In mid-May, the House Energy and Commerce Committee unanimously approved the 21st Century Cures Act, a non-partisan law that brought to fruition the year-long non-partisan efforts of Congressman Fred Upton (R-MI) and Congresswoman Diana DeGette (D-CO). The expectations are that the act’s provisions will allow for rapid breakthrough innovations in healthcare by supporting basic research as well as the drug development and approval process.
In response to this approval, a perspective in the New England Journal of Medicine authored by physicians—experts in healthcare policy and pharmacoeconomics—at Harvard evaluated the implications of the act. The authors welcomed the support promised by 21st Century Cures to funding basic research efforts of the National Institutes of Health (NIH), saying this would “counteract the effects of sequestration and budget cuts that have reduced the purchasing power of the NIH to its lowest level in years.”
While the bill also hoped to accelerate the drug approval process, the authors emphasize that the FDA is already quite adept at moving breakthrough therapies quickly through the process (an average time of 6 to 10 months) to allow for rapid access. They highlight 1 improvement or allowance of the act: the use of nontraditional trial designs such as adaptive designs and the use of Bayesian methods that would be particularly useful for oncology drugs, but warn against the use of shorter trial periods or the use of clinical experience for approval.
With rising global concerns on emergent bacterial resistance to existing antibiotics, the act allows for approval of antibiotics and antifungals, without evidence from a conventional clinical trial, in case of a “serious or life-threatening infection,” say the authors.
Finally, with respect to medical devices, which have always been a topic of contention among stakeholders, the new law provides several useful amendments to validate and standardize devices, but the authors warn that “political forces have introduced provisions that could approve less safe or ineffective drugs and devices.”
Avorn J, Kesselheim AS; 21st Century Cures Act — will it take us back in time? [published online]. N Engl J Med. doi:10.1056/NEJMp1506964.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More